Allspring Global Investments
ACAD icon

Allspring Global Investments’s Acadia Pharmaceuticals ACAD Stock Holding History

Allspring Global Investments’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28.5M Buy
1,132,566
+177,711
+19% +$3.91M 0.04% 469
2026
Q1 		$21.3M Buy
954,855
+296,042
+45% +$7.07M 0.04% 512
2025
Q4 		$17.3M Buy
658,813
+133,393
+25% +$3.19M 0.03% 576
2025
Q3 		$11.2M Buy
525,420
+94,457
+22% +$2.23M 0.02% 684
2025
Q2 		$9.21M Buy
430,963
+120,631
+39% +$2.24M 0.02% 736
2025
Q1 		$5.06M Buy
310,332
+268,714
+646% +$4.88M 0.01% 915
2024
Q4 		$764K Sell
41,618
-80,007
-66% -$1.29M ﹤0.01% 1355
2024
Q3 		$1.87M Buy
121,625
+12,787
+12% +$213K ﹤0.01% 1174
2024
Q2 		$1.77M Buy
108,838
+49,992
+85% +$807K ﹤0.01% 1198
2024
Q1 		$1.09M Sell
58,846
-88,253
-60% -$2.19M ﹤0.01% 1345
2023
Q4 		$4.61M Buy
147,099
+22,008
+18% +$526K 0.01% 972
2023
Q3 		$2.61M Buy
125,091
+87,111
+229% +$2.37M ﹤0.01% 1121
2023
Q2 		$910K Sell
37,980
-51,029
-57% -$1.13M ﹤0.01% 1440
2023
Q1 		$1.68M Buy
89,009
+79,670
+853% +$1.52M ﹤0.01% 1298
2022
Q4 		$149K Sell
9,339
-2,513
-21% -$39.3K ﹤0.01% 1920
2022
Q3 		$193K Buy
11,852
+58
+0.5% +$939 ﹤0.01% 1830
2022
Q2 		$166K Sell
11,794
-50,466
-81% -$942K ﹤0.01% 1877
2022
Q1 		$1.51M Buy
62,260
+3,349
+6% +$81K ﹤0.01% 1653
2021
Q4 		$1.37M Buy
+58,911
New +$1.18M ﹤0.01% 1747

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Allspring Global Investments's ACAD Position: Q2 2026 in Review

Allspring Global Investments increased its Acadia Pharmaceuticals (ACAD) stake by 19% in Q2 2026, buying an estimated $3.91M and bringing the position to 1,132,566 shares worth $28.5M. The position accounts for 0.04% of the portfolio, ranked #469.

Allspring Global Investments first reported a position in ACAD in Q4 2021 and has held it in 19 quarters since. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Allspring Global Investments held 1,132,566 shares of Acadia Pharmaceuticals worth $28.5M as of Q2 2026.
  • Allspring Global Investments bought 177,711 Acadia Pharmaceuticals shares in Q2 2026, an estimated $3.91M.
  • Acadia Pharmaceuticals made up 0.04% of Allspring Global Investments's portfolio in Q2 2026, its #469 holding.
  • Allspring Global Investments first reported a position in Acadia Pharmaceuticals in Q4 2021 and has held it in 19 quarters since.
  • 354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Allspring Global Investments's 13F filing for Q2 2026, filed 13 Aug 2026.